Loading...
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience
Ibrutinib is an oral Bruton’s tyrosine kinase (BTK) inhibitor, which has recently gained approval by the United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with symptomatic Waldenström macroglobulinemia (WM). Herein, we review...
Na minha lista:
| Udgivet i: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959643/ https://ncbi.nlm.nih.gov/pubmed/27493708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716654102 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|